Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — BIO International Convention 2016
38 slides from Aethlon Medical's conference presentation, Jun 7, 2016
Slide 1: Aethlon Medical, Inc. - BIO International Convention
A e thlon Medical, Inc . Nasdaq : AEMD BIO International Convention San Francisco June 7, 2016 Jim Joyce Chairman, CEO
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e thlon ADAPT™ and ELLSA
Slide 3: Immunotherapeutic Technologies to Combat Infectious Disease & Cancer
IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER
Slide 4: Save Lives
SAVE LIVES
Slide 5: Summary
Summary • Clinical - stage Company • Lead therapeutic – The Aethlon Hemopurifier ® – B road - spectrum countermeasure against emerging pandemic threats – Discovered to capture cancer - promoting exosomes • Significant unmet need in cancer care • Exosome Sciences, Inc. (diagnostic subsidiary) – ELLSA
Slide 6: The Aethlon Hemopurifier
The A e thlon Hemopurifier® Broad - s pectrum e limination of circulating viruses, viral particles and bacterial toxins
Slide 7: Deployed Within the Global Infrastructure of Dialysis & CRRT Machines
DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES
Slide 8: The Hemopurifier Mechanism of Action
The Hemopurifier ® Mechanism of Action • Rapid separation of disease targets from the circulatory blood path • Capture of disease targets through adherence to surface structure that provides immune - evasion – Lectin - affinity attachment to high - mannose signature that cloaks pathogen targets from
Slide 9: Therapeutic strategy for viruses not treatable with antivirals
The Hemopurifier ® establishes a therapeutic strategy to address the hundreds of viruses that are not treatable with antiviral drug agents .
Slide 10: FDA approved IDE study currently being conducted
The A e thlon Hemopurifier® FDA approved IDE study currently being conducted
Slide 11: Previous Human Treatment Experiences
Previous Human Treatment Experiences
Slide 12: Broad-Spectrum Human Treatment Experiences
BROAD - SPECTRUM HUMAN TREATMENT EXPERIENCES HIV - AIDS Hepatitis - C Ebola
Slide 13: The Treatment of Ebola Virus
The Treatment of Ebola Virus Frankfurt University Hospital Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)
Slide 14: Hemopurifier therapy administration to a comatose Ebola patient
Hemopurifier® therapy administration to a comatose Ebola patient with multiple - organ failure
Slide 15: Dr. Stefan Büttner Holding Hemopurifier After Ebola Treatment
Dr. Stefan Büttner Holding Hemopurifier® After Ebola Treatment
Slide 16: Ebola Treatment Data Presented at ASN Annual Meeting
Ebola Treatment Data Presented By Dr. Helmut Geiger American Society of Nephrology Annual Meeting • 6.5 hour Hemopurifier® therapy administration • Pre - treatment viral load: 400,000 copies/ml • Post - treatment viral load: 1,000 copies/ml • Patient recovered and returned home
Slide 17: Extracorporeal Virus Elimination for Severe Ebola Virus Disease
Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis • Stefan Bü ttner a Benjamin Koch a Olga Dolnik b Markus Eickmann b Tilo Freiwald a Sarah Rudolf a Jü rgen Engel a Stephan Becker b Claudio Ronco c Helmut Geiger
Slide 18: Top Best Inventions / Most Remarkable Advances in Healthcare
“Top 25 Best Inventions” “11 Most Remarkable Advances in Healthcare”
Slide 19: Pre-clinical Validations
Pre - clinical Validations ( Reported t o date )
Slide 20: In Vitro Hemopurifier Validations
In Vitro Hemopurifier ® Validations • Viruses – Hepatitis C, HIV, Ebola, H1N1 Swine Flu, H5N1 Bird Flu, 1918 Spanish Flu (reconstructed), Monkey Pox, West Nile Virus, Chikungunya and Dengue • Viral Toxins • Ebola glycoprotein ( gp ), HIV gp120, HIV NEF - exosomes • Bacterial Toxins • L ipopolysaccha
Slide 21: Initiated tumor-derived exosome research in 2006
Initiated tumor - derived exosome research in 2006 Considered c ellular debris w ith n o b iological f unction CANCER
Slide 22: Tumor-derived exosomes are significant therapeutic and diagnostic targets
2016 Tumor - derived exosomes are significant therapeutic and diagnostic targets
Slide 23: Tumor-Derived Exosomes
Tumor - Derived Exosomes
Slide 24: Tumor-Derived Exosomes: A Significant Unmet Medical Need in Cancer
Tumor - Derived Exosomes A Significant Unmet Medical Need in Cancer • The seeds of cancer metastasis – Metastasis contributes to 90% of cancer deaths – The mystery of the Soil & Seed Theory of 1889 • Tumor - derived exosomes promote: – Tumorigenesis – Cancer progression – Angiogenesis – Immune - eva
Slide 25: Hemopurifier as adjunct strategy to immuno-oncology drugs
The Hemopurifier ® provides an adjunct strategy to optimize emerging immuno - oncology drugs or improve the benefit of chemotherapeutic regimens
Slide 26: Exosome Sciences
eo0o0ee e0000000 Exosome eoessooee SCIENCES
Slide 27: ELLSA Proprietary exosome isolation platform
ELLSA™ (Enzyme - linked lectin - specific assay) Proprietary exosome isolation platform
Slide 28: ELLSA
ELLSA™ • Isolates disease - origin exosomes from bodily fluids – ELLSA step + specific antibody step to diagnose and monitor a variety of disease indications – Urine based proof - of - principal established in HIV • Identified HIV - specific exosomes in 111 HIV - infected individuals, but not in the
Slide 29: Chronic Traumatic Encephalopathy (CTE)
Chronic Traumatic Encephalopathy (CTE)
Slide 30: TauSome CTE biomarker candidate and DETECT study
• Discovery of CTE biomarker candidate ( TauSome ™) • TauSome testing was conducted in the DETECT study – In collaboration with the Boston University CTE Center • Principal Investigator: Robert Stern Ph.D. – Goal: a test that could detect CTE in living individuals – 78 former NFL players (high risk
Slide 31: Preliminary Study of Plasma Exosomal Tau as Biomarker for CTE
Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy Stern , Tripodis , Baugh, Fritts , Martin, Chaisson , Cantu, Joyce, Shah, Ikezu , Zhang, Gercel - Taylor, & Taylor J Alzheimer’s Disease, 2016 • Findings suggest that TauSome plasma levels may be a
Slide 32: TauSome Concentration by Patient Samples
0 2 4 6 8 10 12 14 16 18 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 TauSome Concentration (x10 9 /mL) Patient Samples *Horizontal lines represent average TauSome concentration for each group. Control Samples
Slide 33: TauSome Next Steps
• TauSome Next Steps (more testing required) – Validate that TauSomes are brain - derived – Refine technique to ELLSA - antibody or other scalable methodology – Initiate TauSome studies in other tauopathies – Initiate TauSome studies in other high - risk CTE groups – TauSome testing to be included i
Slide 34: Summary
Summary • Clinical - stage Company • Lead therapeutic – The Aethlon Hemopurifier ® – B road - spectrum countermeasure against emerging pandemic threats – Discovered to capture cancer - promoting exosomes • Significant unmet need in cancer care • Exosome Sciences, Inc. (diagnostic subsidiary) – ELLSA
Slide 35: Immunotherapeutic Technologies to Combat Infectious Disease & Cancer
IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER
Slide 36: Save Lives
SAVE LIVES
Slide 37: Acknowledgement and Thanks
Acknowledgement and Thanks • Team Aethlon • Battelle Memorial Research Institute • Boston University CTE Center • DaVita Med Center Dialysis • Defense Advanced Research Projects Agency (DARPA ) • Frankfurt University Hospital • Medanta Medicity , Fortis and Apollo Hospitals • Morehouse School of Med
Slide 38: Contact: Aethlon Medical, Inc
CONTACT: A e thlon Medical, Inc 9635 Granite Ridge Drive Suite 100 San Diego, California 92123 Jim Joyce Chairman & CEO jj@aethlonmedical.com 858.459.7800 x301